Advertisement
Advertisement
NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares
30.97
USDSponsored
+0.91
+3.01%
Mar 25, 16:00 UTC -4
Closed
After-Market
30.98
+0.01
+0.03%
NAMS Earnings Reports
Positive Surprise Ratio
NAMS beat 5 of 10 last estimates.
50%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$955.09K
/-$0.50
Implied change from Q4 25 (Revenue/ EPS)
+2884.65%
/-19.35%
Implied change from Q1 25 (Revenue/ EPS)
-67.93%
/+47.06%
NewAmsterdam Pharma Company N.V. Ordinary Shares earnings per share and revenue
On Feb 18, 2026, NAMS reported earnings of -0.62 USD per share (EPS) for Q4 25, missing the estimate of -0.39 USD, resulting in a -57.84% surprise. Revenue reached 32.00 thousand, compared to an expected 5.22 million, with a -99.39% difference. The market reacted with a +1.48% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of -0.50 USD, with revenue projected to reach 955.09 thousand USD, implying an decrease of -19.35% EPS, and increase of 2884.65% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
Relmada Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.28
Surprise
-103.08%
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.01
Surprise
-361.54%
FAQ
What were NewAmsterdam Pharma Company N.V. Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, NewAmsterdam Pharma Company N.V. Ordinary Shares reported EPS of -$0.62, missing estimates by -57.84%, and revenue of $32.00K, -99.39% below expectations.
How did the market react to NewAmsterdam Pharma Company N.V. Ordinary Shares's Q4 2025 earnings?
The stock price moved up 1.48%, changed from $35.24 before the earnings release to $35.76 the day after.
When is NewAmsterdam Pharma Company N.V. Ordinary Shares expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for NewAmsterdam Pharma Company N.V. Ordinary Shares's next earnings report?
Based on 10
analysts, NewAmsterdam Pharma Company N.V. Ordinary Shares is expected to report EPS of -$0.50 and revenue of $955.09K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement